Yahoo Finance

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Spinal cord stimulation eases pain and improves sensation in people with diabetic nerve damage

A multicenter randomized clinical trial led by researchers from the Pain Outcomes Lab at Wake Forest University School of ...
BioWorld

Sangamo presents epigenetic therapy for small fiber neuropathy

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.
BioWorld

Sangamo’s ST-503 receives IND clearance for idiopathic small fiber neuropathy

Sangamo Therapeutics Inc. has received IND clearance from the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy ...
Healio

FDA clears IND application for epigenetic regulator to treat idiopathic neuropathy pain

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...
theepochtimes

Peripheral Neuropathy: Symptoms, Causes, Treatments, and Natural Approaches

Medically reviewed byJimmy Almond, M.D. Peripheral neuropathy (PN) is a severe and complex neurological disorder affecting 20 million to 30 million people in the United States. PN damages nerves ...